Refluxter for Clinicians
Give your reflux patients a high-dose alginate raft, and try it yourself, on us.
Refluxter delivers 1,000+ mg of sodium alginate per serving with calcium carbonate and sodium bicarbonate, a non-systemic, mechanical raft that floats on gastric contents to help limit reflux of acid and pepsin into the esophagus and pharynx. No acid suppression. No chalky liquid. The 1,000+ mg of sodium alginate mirrors the amount used in the European clinical studies of alginate raft therapy, in a capsule your patients can actually get in the U.S.
At a glance
| Sodium alginate / serving | 1,000+ mg |
| Raft forms in | ~10 min |
| Duration per dose | up to ~4 h |
| Absorption | Non-systemic |
| Format | Vegan capsule |
The Refluxter Clinician Handbook
A 17-page clinical reference: mechanism, GERD vs. LPR, dosing & timing, integration with PPI therapy, contraindications, safety and drug spacing, point-of-care counseling scripts, and the alginate evidence base. Print it for your office or hand it to colleagues.
Why clinicians choose Refluxter
|
Study-level alginate dose Over 1,000 mg of sodium alginate per serving, at or above the doses in much of the published raft-therapy literature. The amount was chosen to mirror the European clinical studies of alginate raft therapy. |
Non-systemic mechanism A physical raft barrier. It isn't absorbed and doesn't suppress gastric acid, so it doesn't interfere with digestion or the acid patients need for nutrient absorption. |
pH-independent for LPR Because it blocks reflux mechanically, the raft can help hold back both liquid and gaseous reflux regardless of acidity; relevant when pepsin drives silent-reflux symptoms. |
|
Adherence-friendly capsule Taste-free vegan capsules; no chalky tablet, no gel, no sugar, no aluminum. Easy to carry and to dose after meals or before bed. |
Fills the U.S. availability gap Much of the alginate evidence studied formulations not sold in the U.S. Refluxter is a high-dose alginate your patients can obtain domestically. |
M.D.-formulated, made in the USA Developed by Sarv Kannapiran, M.D., J.D., M.B.A., around the three ingredients the alginate research identifies in the most effective products. |
How the raft works
|
1 · Forms Contact with gastric acid releases CO₂ and sets the alginate into a light, buoyant gel within minutes. |
2 · Floats The low-density raft rises to the top of stomach contents and sits at the gastroesophageal junction as a mechanical barrier. |
3 · Clears The raft stays in the GI tract, is gradually broken down, and is excreted; not absorbed into the bloodstream. |
GERD vs. LPR at a glance
| Feature | GERD | LPR (silent reflux) |
|---|---|---|
| Typical symptoms | Heartburn, chest discomfort, regurgitation, nausea | Chronic cough, hoarseness, throat-clearing, globus, mucus |
| Main injurious agent | Acid | Pepsin (active even at higher pH) |
| Tissue affected | Esophagus (more resilient) | Larynx & pharynx (more delicate) |
| Time to judge response | ~2 weeks of consistent use | A full 8 weeks; mucosa heals gradually |
Patient counseling at a glance
- Dose & timing: 2 capsules with water after meals and/or before bed, up to 8 capsules/day. The bedtime dose, taken last, after the final food or drink, matters most for nighttime and LPR symptoms.
- Set expectations: it's a barrier built through consistent use, not an instant antacid. Judge heartburn/GERD at about 2 weeks and LPR at a full 8 weeks.
- Alongside existing therapy: patients often continue a morning PPI and add Refluxter after meals and at night for breakthrough and nocturnal symptoms.
- Medication spacing: to avoid entrapment in the raft, advise spacing other oral medications and supplements 30–60 minutes before, or ~4 hours after, a Refluxter dose. Separate calcium-sensitive drugs (e.g., levothyroxine, tetracyclines, fluoroquinolones, bisphosphonates) by at least 4 hours.
- Avoid eating right after dosing, which can disrupt a freshly formed raft.
The Clinician Handbook expands each of these into full detail, with dosing tables, safety and sodium/calcium accounting, and ready-to-say counseling scripts.
Who should not use Refluxter
Refluxter carries a product-label warning against use in patients with an esophageal stricture or swallowing disorder (a size 00 capsule and its swelling gel could lodge in a narrowed esophagus), and in patients with an ileostomy or other condition affecting intestinal transit (alginate passes through the small bowel largely intact).
Use with caution and clinician oversight in patients with severe kidney disease (account for sodium and calcium) or a known severe seaweed allergy. See the Clinician Handbook for full contraindications and cautions.
What's in the Refluxter clinician program
|
Free practitioner samples Complimentary Refluxter to evaluate yourself and to hand patients to try. |
Patient discount Patients get the standard 10% off their first order by joining the Refluxter mailing list at nutritist.us. No special code needed. |
Point-of-care materials The Clinician Handbook and patient dosing guidance for your office. |
Request samples & resources
It's our pleasure to provide complimentary samples and patient education materials to licensed clinicians. Tell us where to ship, and note anything special in the additional notes. Order more anytime. Fields marked * are required.
Explore the science
The literature below concerns sodium alginate and raft-forming agents as an ingredient class, provided for your independent professional evaluation. It is not specific to Refluxter. A fuller, annotated list is in the Clinician Handbook.
- Leiman et al. (2017), Alginate therapy is effective for GERD symptoms: systematic review & meta-analysis
- McGlashan et al. (2009), Liquid alginate in the management of laryngopharyngeal reflux (RCT)
- Pizzorni et al. (2022), Magnesium alginate vs. PPI for LPR: non-inferiority RCT
- Rohof et al. (2013), Alginate-antacid localizes to the postprandial acid pocket
- Bor et al. (2019), Alginates: from the ocean to GERD treatment
- More on the Nutritist Science page